The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Share News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 68.00
Bid: 67.00
Ask: 68.60
Change: -3.60 (-5.03%)
Spread: 1.60 (2.388%)
Open: 69.00
High: 69.00
Low: 67.20
Prev. Close: 71.60
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Novacyt gets PHE order for Covid-19 tests

Mon, 16th Mar 2020 09:46

(Sharecast News) - Novacyt said on Monday that Public Health England has decided to use a Covid-19 test developed by its molecular diagnostics division, Primerdesign.
Following the completion of PHE's formal evaluation of the test, as announced last week, the government agency has begun ordering it. Orders are initially for eight hospitals to provide stocks in those locations for four weeks of planned testing, Novacyt said.

The total value of the initial purchase is about ?1m, which is the single largest order the company has received to date for the Covid-19 test.

As of 13 March, Primerdesign had sold and received orders for more than ?3.7m of its CE-Mark and research use only (RUO) Covid-19 tests, which includes the order received from PHE. This represents around eight months of sales for the division under normal circumstances, it said, and is additional revenue to the core Novacyt business.

Chief executive officer Graham Mullis said he was "delighted" that Novacyt will now be supporting one of its home markets "during these challenging times".

"The number of countries Novacyt is now supplying with its Covid-19 test has reached over 60 and we expect this will continue to increase," he added.
More News
2 Aug 2018 13:49

Novacyt Expects Annual Revenue Lower Than Forecast

LONDON (Alliance News) - Novacyt SA said Thursday it expects annual revenue to be lower than expectations due to underperfomance of NOVAprep business.However, the company said that with a

Read more
2 Aug 2018 11:58

Novacyt stumbles as Novaprep business tanks

(Sharecast News) - Novacyt on Thursday confirmed that it will carry out a strategic review after reporting that full-year group revenue will be lower than previously expected due to losses in its Novaprep business.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.